title: Broad targeting of angiogenesis for cancer prevention and therapy.
abstract: Deregulation of angiogenesis--the growth of new blood vessels from an existing vasculature--is a main driving force in many severe human diseases including cancer. As such, tumor angiogenesis is important for delivering oxygen and nutrients to growing tumors, and therefore considered an essential pathologic feature of cancer, while also playing a key role in enabling other aspects of tumor pathology such as metabolic deregulation and tumor dissemination/metastasis. Recently, inhibition of tumor angiogenesis has become a clinical anti-cancer strategy in line with chemotherapy, radiotherapy and surgery, which underscore the critical importance of the angiogenic switch during early tumor development. Unfortunately the clinically approved anti-angiogenic drugs in use today are only effective in a subset of the patients, and many who initially respond develop resistance over time. Also, some of the anti-angiogenic drugs are toxic and it would be of great importance to identify alternative compounds, which could overcome these drawbacks and limitations of the currently available therapy. Finding "the most important target" may, however, prove a very challenging approach as the tumor environment is highly diverse, consisting of many different cell types, all of which may contribute to tumor angiogenesis. Furthermore, the tumor cells themselves are genetically unstable, leading to a progressive increase in the number of different angiogenic factors produced as the cancer progresses to advanced stages. As an alternative approach to targeted therapy, options to broadly interfere with angiogenic signals by a mixture of non-toxic natural compound with pleiotropic actions were viewed by this team as an opportunity to develop a complementary anti-angiogenesis treatment option. As a part of the "Halifax Project" within the "Getting to know cancer" framework, we have here, based on a thorough review of the literature, identified 10 important aspects of tumor angiogenesis and the pathological tumor vasculature which would be well suited as targets for anti-angiogenic therapy: (1) endothelial cell migration/tip cell formation, (2) structural abnormalities of tumor vessels, (3) hypoxia, (4) lymphangiogenesis, (5) elevated interstitial fluid pressure, (6) poor perfusion, (7) disrupted circadian rhythms, (8) tumor promoting inflammation, (9) tumor promoting fibroblasts and (10) tumor cell metabolism/acidosis. Following this analysis, we scrutinized the available literature on broadly acting anti-angiogenic natural products, with a focus on finding qualitative information on phytochemicals which could inhibit these targets and came up with 10 prototypical phytochemical compounds: (1) oleanolic acid, (2) tripterine, (3) silibinin, (4) curcumin, (5) epigallocatechin-gallate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9) withaferin A and (10) resveratrol. We suggest that these plant-derived compounds could be combined to constitute a broader acting and more effective inhibitory cocktail at doses that would not be likely to cause excessive toxicity. All the targets and phytochemical approaches were further cross-validated against their effects on other essential tumorigenic pathways (based on the "hallmarks" of cancer) in order to discover possible synergies or potentially harmful interactions, and were found to generally also have positive involvement in/effects on these other aspects of tumor biology. The aim is that this discussion could lead to the selection of combinations of such anti-angiogenic compounds which could be used in potent anti-tumor cocktails, for enhanced therapeutic efficacy, reduced toxicity and circumvention of single-agent anti-angiogenic resistance, as well as for possible use in primary or secondary cancer prevention strategies.
authors.affiliation: Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: zwang0@partners.org.
authors.forename: Zongwei
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Oncology, Linköping University, Linköping, Sweden; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
authors.forename: Charlotta
authors.initials: C
authors.lastname: Dabrosin
authors.affiliation: Medicine and Research Services, Veterans Affairs San Diego Healthcare System & University of California, San Diego, San Diego, CA, USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Yin
authors.affiliation: Medicine and Research Services, Veterans Affairs San Diego Healthcare System & University of California, San Diego, San Diego, CA, USA.
authors.forename: Mark M
authors.initials: MM
authors.lastname: Fuster
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Arreola
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: W Kimryn
authors.initials: WK
authors.lastname: Rathmell
authors.affiliation: Molecular Therapy and Pharmacogenomics Unit, AO Isituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
authors.affiliation: Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
authors.forename: Ganji P
authors.initials: GP
authors.lastname: Nagaraju
authors.affiliation: Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
authors.forename: Bassel
authors.initials: B
authors.lastname: El-Rayes
authors.affiliation: Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy; National Cancer Institute Giovanni Paolo II, Bari, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Ribatti
authors.affiliation: Department of Biology, Alderson Broaddus University, Philippi, WV, USA.
authors.forename: Yi Charlie
authors.initials: YC
authors.lastname: Chen
authors.affiliation: Department of Orthopedic Surgery, Arthroplasty and Regenerative Medicine, Nara Medical University, Nara, Japan.
authors.forename: Kanya
authors.initials: K
authors.lastname: Honoki
authors.affiliation: Department of Orthopedic Surgery, Arthroplasty and Regenerative Medicine, Nara Medical University, Nara, Japan.
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Fujii
authors.affiliation: Physics Department, School of Applied Mathematics and Physical Sciences, National Technical University of Athens, Athens, Greece.
authors.forename: Alexandros G
authors.initials: AG
authors.lastname: Georgakilas
authors.affiliation: Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN, USA.
authors.forename: Somaira
authors.initials: S
authors.lastname: Nowsheen
authors.affiliation: Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
authors.forename: Amedeo
authors.initials: A
authors.lastname: Amedei
authors.affiliation: Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Niccolai
authors.affiliation: Department of Biology, College of Science, United Arab Emirate University, United Arab Emirates; Faculty of Science, Cairo University, Cairo, Egypt.
authors.forename: Amr
authors.initials: A
authors.lastname: Amin
authors.affiliation: Department of Chemistry, College of Science, United Arab Emirate University, United Arab Emirates.
authors.forename: S Salman
authors.initials: SS
authors.lastname: Ashraf
authors.affiliation: University of Illinois at Urbana Champaign, Urbana, IL, USA.
authors.forename: Bill
authors.initials: B
authors.lastname: Helferich
authors.affiliation: University of Illinois at Urbana Champaign, Urbana, IL, USA.
authors.forename: Xujuan
authors.initials: X
authors.lastname: Yang
authors.affiliation: School of Chemical and Bio Technology, SASTRA University, Thanjavur, India.
authors.forename: Gunjan
authors.initials: G
authors.lastname: Guha
authors.affiliation: School of Chemical and Bio Technology, SASTRA University, Thanjavur, India.
authors.forename: Dipita
authors.initials: D
authors.lastname: Bhakta
authors.affiliation: Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Ciriolo
authors.affiliation: Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
authors.forename: Katia
authors.initials: K
authors.lastname: Aquilano
authors.affiliation: Ovarian and Prostate Cancer Research Trust Laboratory, Guilford, Surrey, UK.
authors.forename: Sophie
authors.initials: S
authors.lastname: Chen
authors.affiliation: New York Medical College, New York City, NY, USA.
authors.forename: Dorota
authors.initials: D
authors.lastname: Halicka
authors.affiliation: Department of Comparative Pathobiology, Purdue University Center for Cancer Research, West Lafayette, IN, USA.
authors.forename: Sulma I
authors.initials: SI
authors.lastname: Mohammed
authors.affiliation: School of Medicine, Wayne State University, Detroit, MI, USA.
authors.forename: Asfar S
authors.initials: AS
authors.lastname: Azmi
authors.affiliation: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
authors.forename: Alan
authors.initials: A
authors.lastname: Bilsland
authors.affiliation: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
authors.forename: W Nicol
authors.initials: WN
authors.lastname: Keith
authors.affiliation: Department of Medical, and Health Sciences, Linköping University, Linköping, Sweden; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Electronic address: lasse.jensen@liu.se.
authors.forename: Lasse D
authors.initials: LD
authors.lastname: Jensen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001808:Blood Vessels / Q000187:drug effects / Q000254:growth & development / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000517:prevention & control / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic
keywords: Angiogenesis; Anti-angiogenic; Cancer; Phytochemicals; Treatment